PACB Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.5% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc., is engaged in design, development and commercialization of innovative tools for biological research. The Company' products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS.
Sector
Technology
Industry
Scientific / Technical Instruments